PortfoliosLab logo

Clover Biopharmaceuticals Ltd (2197.HK)

Equity · Currency in HKD · Last updated Jun 2, 2023

Company Info

ISINKYG2280A1076
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$1.58B
EPSHK$0.00
PE RatioN/A
PEG RatioN/A
Revenue (TTM)HK$0.00
Gross Profit (TTM)-HK$475.64M
EBITDA (TTM)-HK$2.34B
Year RangeHK$1.12 - HK$6.09
Target PriceHK$3.66

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of HK$10,000 in Clover Biopharmaceuticals Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%2023FebruaryMarchAprilMayJune
-74.48%
2.41%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with 2197.HK

Clover Biopharmaceuticals Ltd

Return

Clover Biopharmaceuticals Ltd had a return of -56.37% year-to-date (YTD) and -71.32% in the last 12 months. Over the past 10 years, Clover Biopharmaceuticals Ltd had an annualized return of -79.77%, outperforming the S&P 500 benchmark which had an annualized return of -7.44%.


PeriodReturnBenchmark
1 month-35.06%0.91%
Year-To-Date-56.37%7.82%
6 months-75.91%2.41%
1 year-71.32%-2.53%
5 years (annualized)-79.77%-7.44%
10 years (annualized)-79.77%-7.44%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-2.32%-1.19%-35.20%14.20%-38.38%
2022203.31%-52.82%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Clover Biopharmaceuticals Ltd (2197.HK) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
2197.HK
Clover Biopharmaceuticals Ltd
-0.74
^GSPC
S&P 500
0.10

Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Clover Biopharmaceuticals Ltd Sharpe ratio is -0.74. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


-0.80-0.60-0.40-0.200.000.202023FebruaryMarchAprilMayJune
-0.74
0.07
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

Dividend History


Clover Biopharmaceuticals Ltd doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%2023FebruaryMarchAprilMayJune
-92.03%
-11.93%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Clover Biopharmaceuticals Ltd. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Clover Biopharmaceuticals Ltd is 92.03%, recorded on Jun 1, 2023. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.03%Dec 14, 2021359Jun 1, 2023
-29.97%Nov 8, 20213Nov 10, 202121Dec 9, 202124

Volatility Chart

The current Clover Biopharmaceuticals Ltd volatility is 22.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%2023FebruaryMarchAprilMayJune
22.62%
3.46%
2197.HK (Clover Biopharmaceuticals Ltd)
Benchmark (^GSPC)